Written and maintained by CASRAI Editorial Board
Published · Last updated
On this page
A medication earns high-alert status not because it causes errors more often than other drugs, but because a single error with it is far more likely to kill or permanently injure a patient. The Institute for Safe Medication Practices (ISMP) publishes the reference most US hospitals build from: the List of High-Alert Medications in Acute Care Settings. ISMP last updated that list in January 2024, when it added tranexamic acid injection; the list itself dates to 1989, when ISMP first published six high-alert drugs. It names the drug classes where ordinary vigilance is not enough and the institution has to build structural defenses — checks that catch an error before it reaches the patient, not training that asks staff to be more careful.
This page is written for patient-safety officers, pharmacy leadership, quality directors, risk managers, and P&T committee members who own a hospital’s high-alert medication program — not as clinical guidance for a specific order or patient. It covers what distinguishes ISMP’s list from an ordinary risk list, three safeguard strategies (independent double-checks, standardized concentrations, and auto-stop orders) matched to the specific failure mode each one is built to catch, and the step ISMP itself flags as commonly skipped: turning a published national list into an institution-specific document with a documented safeguard attached to every single entry.
What “high-alert” means, and what it doesn’t
ISMP defines high-alert medications as drugs that bear a heightened risk of causing significant patient harm when used in error — not drugs with a higher raw error rate. Errors with insulin, concentrated potassium chloride, or IV opioids happen at roughly the same frequency as errors with lower-risk drugs; what differs is the consequence when one gets through. That distinction is the reason the safety strategy for this list looks different from ordinary medication-error prevention: instead of relying on a clinician catching the mistake, the program is built to make the error structurally harder to make, or to intercept it before it reaches the patient, because the cost of a miss is so much higher.
This is also distinct from a hazardous drug list (handling risk to staff — chemotherapy spill precautions, closed-system transfer devices, USP <800>) and from a look-alike/sound-alike (LASA) list (see building a LASA medication list), which addresses a name-confusion risk rather than a dosing/administration risk. A drug can appear on more than one list — several chemotherapy agents are both high-alert and hazardous — but the three lists exist for different reasons and call for different countermeasures. Conflating them is a common early mistake when a program is first being built.
What is the current ISMP high-alert medication list?
The current ISMP List of High-Alert Medications in Acute Care Settings is the 2024 edition, which added tranexamic acid injection; ISMP’s own list page cites it as “ISMP; 2024”. Searches for a “2026” list lead to this same document, so the date on your policy should be the revision date printed on the PDF.
ISMP’s List of High-Alert Medications in Acute Care Settings
ISMP maintains the acute-care list (a companion list exists for community/ambulatory settings) as a set of drug classes, plus a shorter set of specific individual medications called out by name because the class-level grouping would otherwise miss them. The classes below are the ones this page uses as the stable core when discussing safeguards; the 2024 PDF is the authority on exact class boundaries and named drugs:
- Anesthetic agents, general, inhaled and IV
- Antiarrhythmics, IV
- Antithrombotic agents, including anticoagulants, factor Xa inhibitors, direct thrombin inhibitors, and thrombolytics
- Chemotherapeutic agents, parenteral and oral
- Concentrated electrolytes for injection (including potassium chloride and potassium phosphate)
- Epidural and intrathecal medications
- Inotropic medications, IV
- Insulin, subcutaneous and IV
- Moderate sedation agents, IV and oral
- Neuromuscular blocking agents
- Opioids, including patient-controlled analgesia (PCA)
- Parenteral nutrition solutions
Class boundaries and specific named drugs change between revisions, so pull the current PDF directly from ISMP (hosted by ECRI, linked under Sources) before building or auditing a formulary against it, and re-pull it on whatever cadence your P&T committee reviews the formulary. ISMP’s announcement of the update is dated January 12, 2024, and the Agency for Healthcare Research and Quality’s PSNet entry for the list is dated January 14, 2024; the revision date printed on the document itself is the one to cite in policy. The list page cites the document as “ISMP List of High-Alert Medications in Acute Care Settings (ISMP; 2024).”
What changed in the 2024 update
According to ISMP’s announcement, the 2024 revision was based on a 2023 survey, error reports submitted to ISMP, and expert review. The one addition ISMP highlighted was tranexamic acid injection; the announcement mentions no removals. ISMP also noted that respondents recognised potassium phosphate injection and oxytocin more often as high-alert than before. The history matters for local lists: ISMP first published six high-alert drugs in 1989, and the list has grown by evidence of harm since, which is why a list copied once and never refreshed drifts out of date.
Worked example: tranexamic acid
Tranexamic acid shows how a list entry should turn into specific safeguards rather than a general caution. ISMP’s statement describes the failure mode: errors often involve storage and mix-ups with look-alike anesthetic vials in surgical and procedural areas, and when tranexamic acid is given neuraxially (into the spinal or epidural space) it is a potent neurotoxin, with mortality of about 50% according to ISMP. The error is a selection and storage problem, not a calculation problem, so a double-check on dose or a standardized infusion concentration would not address it.
The matching safeguards appear in Best Practice 20 of ISMP’s Targeted Medication Safety Best Practices for Hospitals 2024–2025, new in that edition: use premixed IV bags; do not store tranexamic acid in the anesthesia tray if possible; keep it physically separate from local anesthetics; and consider a vial-cap label reading “Contains Tranexamic Acid.” Each safeguard attacks the mix-up at a different point (product form, storage location, and the moment of picking up the vial), which is the layering idea described below.
Why these classes specifically — the failure mode drives the safeguard
Each entry on the list earns its place through a specific, recurring failure pattern, and that pattern is what should determine which safeguard gets attached to it — a generic “be careful” policy note does not address any of them:
- Insulin and IV opioids — narrow therapeutic index plus a common, easy-to-make error (unit-to-mL confusion, decimal placement, wrong concentration selected on an infusion pump) that produces a rapid, severe, sometimes irreversible physiologic consequence (hypoglycemic coma, respiratory depression).
- Concentrated electrolytes (KCl, hypertonic saline) — the undiluted or wrongly-diluted form is lethal if pushed or infused too fast, and the vial or bag looks unremarkable next to a correctly diluted product; the failure is a storage/selection error, not a calculation error.
- Anticoagulants and thrombolytics — a narrow window between therapeutic and hemorrhagic effect, compounded by renal function, drug interactions, and lab-result lag, so the risk accumulates silently over a course of therapy rather than showing up at the moment of administration.
- Neuromuscular blocking agents — render a patient unable to breathe or signal distress; an error (wrong patient, given outside a controlled airway setting) is catastrophic and the patient cannot self-report the problem.
- Chemotherapy — dosing is frequently individualized to body-surface-area or renal function, so a transcription or calculation error compounds an already-narrow safety margin, and many agents cause harm that is not reversible once administered.
The three core safeguard strategies, matched to the failure mode
Independent double-checks
An independent double-check requires a second clinician to derive the dose, rate, or pump setting independently — from the order, not from what the first clinician already entered — and then compare results. A check where the second person simply confirms what’s already on the screen catches almost nothing, because it inherits the first person’s error along with their conclusion; ISMP’s own guidance on this point is explicit that the value of the check depends entirely on the second calculation being performed cold. This is the right safeguard where the failure mode is a calculation or programming error that a second independent calculation would catch: insulin drip rates, heparin drip titration, chemotherapy dosing, and PCA pump programming are the classic applications. Because independent double-checks carry a real workflow cost and lose effectiveness with overuse (staff start treating them as a formality once every order requires one), most programs restrict the requirement to the highest-risk subset of orders — typically high-alert IV infusions and chemotherapy — rather than the entire high-alert list. Overusing any such check also feeds alert fatigue.
Standardized concentrations
Standardizing the concentrations available for high-alert IV infusions — a single approved concentration per drug per care area, built into the smart-pump drug library so the nurse selects the drug rather than entering a concentration — removes the step in the workflow where a math error most often happens. This is the right safeguard for drugs administered as a continuous infusion at a rate calculated from concentration — opioids, insulin, heparin, and vasopressors are the standard targets — because it doesn’t just reduce error likelihood, it eliminates the calculation step entirely for the most common order pattern. It does not help with a storage-selection error (the wrong vial pulled from the shelf) or a wrong-patient error, which is why it is deployed alongside, not instead of, the other two strategies.
Auto-stop (hard-stop) orders
An auto-stop order builds an expiration into the order itself — the medication stops administering, or the order requires active renewal, after a defined interval — rather than continuing indefinitely until someone remembers to reassess. This targets a different failure mode from the two above: therapy that was appropriate when started but becomes unsafe as the patient’s status changes, and nobody re-evaluates it because nothing forces the question. Anticoagulation (renal function shifts, a new interacting drug, an upcoming procedure), moderate sedation, and opioid orders for acute pain are the standard applications — a time-limited or renewal-forcing order converts “someone should have caught that” into a system behavior that happens whether or not anyone remembers to look.
How ISMP says to use the list
ISMP-authored guidance on using the list (published in Pharmacy Times) and the strategies listed on the ISMP list page converge on a short set of principles:
- Understand the cause first. Use your own error reports and root cause analyses, and the published literature, to see how errors with each drug actually happen before choosing a safeguard.
- Layer strategies. No single safeguard is reliable alone; combine several.
- Favor reliable over low-leverage strategies. Automation, forcing functions and alerts are more dependable than reminders, policies and education, which depend on memory and vigilance.
- Cover many steps of the process. Safeguards should span ordering, storage, preparation, dispensing and administration, not only the bedside.
- Plan for sustainability. A safeguard that staff work around, or that depends on a single champion, will lapse.
- Make the list easy to find. Communicate it electronically and in a searchable form.
- Audit and ask staff. Check whether safeguards are used as designed and collect feedback from the people who use them.
The ISMP list page names these suggested strategies: standardize ordering, storage, preparation and administration; improve access to information; limit access; use auxiliary labels and automated alerts; and build in redundancies.
Link to ISMP’s Targeted Medication Safety Best Practices
The list says which drugs need structural defenses; ISMP’s Targeted Medication Safety Best Practices say what defenses to build. The 2024–2025 edition (updated every two years) includes several practices that map directly onto high-alert drugs. Best Practice 8 calls for administering all medication and hydration infusions through a programmable infusion pump using dose error-reduction systems, with an exception when the needed rate falls beyond the pump’s limits, and recommends bi-directional EHR interoperability. Best Practice 17 calls for a single concentration and bag size for both antepartum and postpartum oxytocin infusions. Best Practice 19 addresses high-alert medications generally by layering multiple strategies. Best Practice 20 covers tranexamic acid, as above. The data table below this article maps each practice to the failure mode it addresses and the type of safeguard; see also this site’s guide to ISMP Targeted Medication Safety Best Practices.
Acute-care list versus community and ambulatory list
ISMP publishes a separate list for community and ambulatory settings. A hospital that also runs clinics, infusion centers or outpatient pharmacies should check which list fits each location rather than applying the acute-care list everywhere.
Building an institution-specific list — the step most hospitals skip
The most common gap in a high-alert medication program is not omitting the ISMP list — it’s adopting it unchanged as a policy attachment, with no safeguard actually mapped to any specific entry. A national list describes categories of risk in the abstract; it does not know your formulary, your smart-pump library, your order sets, or your own near-miss history. Building the institution-specific version means, for every drug on your formulary that falls into an ISMP class:
- Confirm it’s actually on your formulary and identify every route/form in active use (a drug can be high-alert in one form on your list and not stocked in another).
- Pull internal event-reporting and near-miss data for that drug or class — your own history is often a better predictor of where the next error happens than the national list alone.
- Assign at least one of the three safeguard strategies above to the entry, matched to its actual failure mode as described above — not a default “double-check everything” rule, which erodes compliance on the orders that need it most.
- Confirm the safeguard is actually built into the system it needs to live in — the smart-pump library, the EHR order set, the auto-stop interval in the pharmacy system — not just written into a policy document nobody consults at the point of administration.
- Check that barcode medication administration scanning covers each entry, then route the finished list through P&T committee approval and set a review cadence tied to ISMP’s own revision schedule and to your internal event data.
Accredited hospitals are also expected to maintain a written, institution-specific high-alert medication list with defined safe-use processes as part of their medication management standards — the exact standard number and wording vary by accreditation manual edition, so confirm the current citation against your organization’s live accreditation manual rather than citing a specific standard number from this page.
Frequently asked questions
Is the ISMP high-alert list the same as a hazardous drug list?
No. High-alert status is about the consequence of an administration error to the patient. Hazardous drug status (governed separately, notably by USP <800>) is about handling risk to staff — exposure during preparation and administration. Some drugs, chemotherapy agents especially, are on both lists for different reasons, and each list calls for a different set of controls.
When was the ISMP high-alert list last updated, and what was added?
ISMP announced the update on January 12, 2024. The addition it highlighted was tranexamic acid injection.
Is there a 2026 version of the ISMP high-alert medication list?
Not that ISMP’s list page shows. It still cites the 2024 edition, so use that PDF and re-check ISMP before each formulary review.
Is tranexamic acid a high-alert medication?
Yes. ISMP added tranexamic acid injection to its acute-care list in the 2024 update, citing storage and look-alike vial mix-ups and severe harm when given neuraxially.
How many drugs were on the first ISMP high-alert list?
ISMP first published six high-alert drugs in 1989; according to ISMP, they are still on the list.
Is there a separate list for ambulatory and community settings?
Yes. ISMP publishes a separate high-alert list for community and ambulatory care.
Does ISMP recommend smart pumps for high-alert infusions?
Best Practice 8 of the 2024–2025 Targeted Medication Safety Best Practices for Hospitals recommends giving all medication and hydration infusions through a programmable pump with dose error-reduction systems, with an exception for rates beyond the pump’s limits.
Does posting the ISMP list satisfy accreditation requirements?
Not by itself. Accreditors expect a written, institution-specific list and a process for safe use; posting a national list on the internet is not generally sufficient. Check the current manual of your accrediting body for the exact standard.
Do all hospitals use the identical ISMP list?
No, and they shouldn’t. ISMP publishes the national reference; each institution is expected to adapt it to its own formulary, care settings, and event history, then attach specific safeguards to each entry — that adaptation step is the actual subject of this page and the part most commonly skipped.
What’s the difference between an independent double-check and a routine verification?
A routine verification has the second person confirm what the first person already entered. An independent double-check has the second person calculate the dose, rate, or setting from the original order without seeing the first person’s result, then compare. Only the independent version reliably catches a calculation error, because a confirmation check inherits the first person’s mistake along with their answer.
Why not just require an independent double-check on every high-alert order?
Because the safeguard’s effectiveness depends on staff treating it as a genuine independent recalculation rather than a rubber stamp, and requiring it on every order — including low-complexity, low-risk ones — is the fastest way to turn it into exactly that. Most programs reserve the requirement for the subset of orders where a calculation error is the actual failure mode (infusion rates, chemotherapy dosing, PCA programming) and use standardized concentrations or auto-stop orders for the classes where those safeguards fit the risk better.
Sources (accessed 2026-11-13)
- ISMP Updates High-Alert Medication List (ECRI/ISMP news, January 2024).
- Three New Best Practices in the 2024–2025 Targeted Medication Safety Best Practices for Hospitals (ECRI/ISMP).
- AHRQ PSNet entry for ISMP’s list.
- High-alert medication list is effective when combined with risk-reduction strategies (Pharmacy Times).
- Institute for Safe Medication Practices, List of High-Alert Medications in Acute Care Settings, hosted by ECRI.
- Institute for Safe Medication Practices, ISMP List of Confused Drug Names (the related look-alike/sound-alike reference).
- See also this site’s guide to tall man lettering for the FDA and ISMP name-differentiation lists that address the LASA risk overlapping several high-alert classes.
Data: ISMP Targeted Best Practices and list guidance mapped to high-alert medication failure modes (2024-2025)
Compiled from ECRI/ISMP's 2024-2025 Targeted Medication Safety Best Practices announcement and ISMP's January 2024 high-alert list update; maps each practice or list-update item to the failure mode it addresses and the safeguard type. Wording quoted or paraphrased from the sources; no values estimated.
Period covered: 2024/2025. Coverage: United States.
| Item | Failure mode addressed | Safeguard type | Source wording (quoted or paraphrased) | Edition or date |
|---|---|---|---|---|
| Best Practice 8: dose error-reduction smart pumps | Programming or concentration-entry error on infusions | Technology (forcing function / decision support) | Administer all medication and hydration infusions via a programmable infusion pump utilizing dose error-reduction systems; exception for rates beyond pump limits | 2024-2025 |
| Best Practice 17: oxytocin infusions | Concentration and bag-size variation | Standardization | Standardize to a single concentration and bag size for antepartum and postpartum oxytocin infusions | 2024-2025 |
| Best Practice 19: high-alert medications | Single safeguard failing | Layered strategies | Layers multiple strategies across the medication-use process for high-alert medications | 2024-2025 |
| Best Practice 20: tranexamic acid | Wrong-route/storage mix-up with look-alike anesthetic vials | Storage separation, premixed product, labeling | Use premixed IV bags; do not store in an anesthesia tray if possible; keep separate from local anesthetics; consider vial-cap label | 2024-2025 (new) |
| High-alert list update: tranexamic acid injection added | Neuraxial administration after storage/look-alike mix-up | List inclusion | Added to ISMP List of High-Alert Medications in Acute Care Settings; neuraxial administration mortality about 50% per ISMP | January 2024 |
Sources
- Three New Best Practices in the 2024-2025 Targeted Medication Safety Best Practices for Hospitals (ECRI/ISMP) (accessed 2026-11-13)
- ISMP Updates High-Alert Medication List (ECRI/ISMP) (accessed 2026-11-13)
Compiled by CASRAI from the sources above. Free to reuse under CC BY 4.0 with attribution.







